Metformin FDA Approval History

Why Metformin Took 40 Years to Reach the U.S.

Metformin was first used clinically in France in 1957, yet American patients waited until the end of 1994. The delay was not random. It traced directly to a sister compound, phenformin, which the FDA pulled from the U.S. market in 1977 after phenformin caused fatal lactic acidosis at rates between 40 and 64 cases per 100,000 patient-years 1. That withdrawal cast a regulatory shadow over the entire biguanide class, and sponsors had little incentive to pursue a new application while the phenformin stigma persisted.

Bristol-Myers Squibb eventually filed NDA 020357 for Glucophage, backed by multicenter trials conducted largely in the late 1980s and early 1990s. The key data showed HbA1c reductions of 1.5 to 2.0 percentage points versus placebo without the weight gain seen with sulfonylureas 2. The FDA's Endocrinologic and Metabolic Drugs Advisory Committee reviewed the application and voted favorably, noting that metformin's lactic acidosis rate was roughly one-tenth that of phenformin. On December 29, 1994, the agency granted approval for metformin hydrochloride 500 mg and 850 mg tablets as monotherapy and combination therapy for type 2 diabetes 3.

The approval made the United States one of the last major markets to adopt metformin. By that point, the drug had accumulated over 30 years of post-market data in Europe, the United Kingdom, Canada, and parts of Asia.

The 1998 UKPDS Milestone

Two words changed metformin's trajectory: cardiovascular benefit. The United Kingdom Prospective Diabetes Study (UKPDS 34), published in The Lancet in 1998, randomized 1,704 overweight patients with newly diagnosed type 2 diabetes and found that metformin reduced diabetes-related death by 42% and all-cause mortality by 36% compared with conventional diet therapy alone 4. No other oral glucose-lowering drug had demonstrated a mortality reduction in a randomized trial at that scale.

UKPDS 34 did not simply validate metformin. It created a new standard. The American Diabetes Association (ADA) soon after positioned metformin as the preferred first-line pharmacotherapy for type 2 diabetes, a recommendation that has survived every subsequent guideline revision for over two decades 5. Dr. Rury Holman, the UKPDS principal investigator, stated at the time: "Metformin should be considered as the first-line pharmacological therapy in overweight diabetic patients."

The trial's 10-year post-intervention follow-up, published in 2008, confirmed that the mortality benefit persisted even after treatment differences between groups had disappeared, a phenomenon the investigators termed a "legacy effect" 6.

Label Expansions and Formulation Milestones

Metformin's label did not stay static after 1994. Each revision broadened access.

October 2000 saw the approval of Glucophage XR (NDA 021202), an extended-release formulation designed for once-daily dosing. The XR version reduced gastrointestinal side effects, which are the primary reason roughly 5 to 10% of patients discontinue immediate-release metformin 7.

2002 marked the first generic approvals for immediate-release metformin, driving the average monthly cost below $10 and cementing the drug's role in resource-limited formularies. Today, a 30-day supply of generic metformin costs between $4 and $12 at most U.S. pharmacies.

Combination products followed in rapid succession. The FDA approved metformin co-formulated with glipizide (2002), glyburide (2004), pioglitazone (Actoplus Met, 2005), sitagliptin (Janumet, 2007), saxagliptin (Kombiglyze XR, 2010), linagliptin (Jentadueto, 2012), canagliflozin (Invokamet, 2014), dapagliflozin (Xigduo XR, 2014), empagliflozin (Synjardy, 2015), and ertugliflozin (Segluromet, 2017) 3. This list is not exhaustive, but it illustrates a pattern: nearly every new diabetes drug class sought a fixed-dose combination with metformin as part of its commercial strategy.

Pediatric labeling was added for patients aged 10 to 16 years with type 2 diabetes, making metformin one of the few oral antihyperglycemics approved for children 8.

The Lactic Acidosis Black Box Warning

Metformin has carried a black box warning for lactic acidosis since its original 1994 labeling. The warning was a direct inheritance from the phenformin era. In practice, metformin-associated lactic acidosis (MALA) is rare. A Cochrane systematic review of 347 comparative trials and cohort studies found no cases of fatal or nonfatal lactic acidosis in 70,490 patient-years of metformin exposure, and the pooled incidence of lactic acidosis was no greater in metformin users than in non-metformin users 9.

Measured lactate levels may rise modestly during metformin therapy. But clinically significant lactic acidosis almost always occurs in the setting of acute kidney injury, sepsis, or tissue hypoperfusion, meaning the drug is a cofactor rather than a sole cause. Dr. Silvio Inzucchi of Yale School of Medicine noted in a 2014 review: "The evidence linking metformin to lactic acidosis is surprisingly weak, and the black box warning has likely prevented its use in many patients who would benefit from it" 10.

Despite repeated calls from endocrinologists and professional societies to downgrade or remove the black box, the FDA has retained it. The agency's rationale is that the warning functions as a reminder to check renal function before and during therapy.

The 2016 Renal Dosing Revision

For over two decades, the metformin label contraindicated the drug in patients with serum creatinine levels at or above 1.5 mg/dL in men and 1.4 mg/dL in women. These thresholds were crude. They excluded many older adults with normal or near-normal kidney function simply because of age-related creatinine variation.

In April 2016, the FDA issued a Drug Safety Communication revising the renal contraindication to an eGFR-based framework 11:

• eGFR ≥45 mL/min/1.73 m²: no renal contraindication.
• eGFR 30 to 44 mL/min/1.73 m²: metformin may be initiated with caution; dose reduction recommended. Existing patients may continue with monitoring.
• eGFR <30 mL/min/1.73 m²: metformin is contraindicated.

This revision was grounded in a systematic review the FDA conducted of published literature and post-market surveillance data. The agency concluded that "metformin can be used safely in patients with mild impairment in kidney function and in some patients with moderate impairment." An estimated 100,000 additional U.S. patients with stage 3a chronic kidney disease became eligible for metformin therapy after this label change 12.

Contrast Agent and Surgical Holds

The metformin label includes recommendations to withhold the drug before iodinated contrast procedures and before surgery. The concern is that contrast-induced nephropathy or perioperative renal stress could impair metformin clearance and precipitate lactic acidosis.

Current American College of Radiology (ACR) guidelines specify that metformin should be held only for patients with eGFR <30 mL/min/1.73 m² or those receiving intra-arterial contrast with eGFR 30 to 44 mL/min/1.73 m² 13. For patients with normal renal function receiving standard contrast, routine metformin interruption is no longer required. This is a meaningful shift from the blanket "hold metformin for 48 hours" instruction that was standard practice through the early 2010s.

The 2020 NDMA Contamination Recalls

In February 2020, an independent laboratory (Valisure) filed a citizen petition reporting that certain extended-release metformin products contained N-nitrosodimethylamine (NDMA), a probable carcinogen, above the FDA's acceptable daily intake limit of 96 nanograms per day 14.

The FDA subsequently tested batches from multiple manufacturers and issued recalls for specific lots that exceeded NDMA limits. Not all extended-release metformin was affected. The agency explicitly stated that patients should not stop taking metformin without consulting their prescriber, because the risk of uncontrolled diabetes outweighed the potential cancer risk from short-term NDMA exposure.

By mid-2021, the most heavily affected lots had been removed from the market, manufacturers had implemented new testing protocols, and the FDA published updated guidance on nitrosamine impurity limits for metformin products 15. The NDMA episode did not change metformin's clinical recommendations, but it prompted broader pharmaceutical industry scrutiny of nitrosamine contamination across multiple drug classes.

Ongoing Regulatory and Research Developments

Metformin's regulatory story is still being written. Several active areas may generate future label or approval changes.

TAME Trial (Targeting Aging with Metformin): This NIH-supported, multicenter trial is testing whether metformin 1,500 mg daily delays the onset of age-related diseases (cardiovascular disease, cancer, dementia, mortality) in 3,000 adults aged 65 to 79 without diabetes 16. If positive, it could lead to the first FDA-approved indication for an "aging" endpoint, a regulatory category that does not currently exist.

Cancer risk reduction: Observational data from over 40 studies suggest metformin users have 10 to 40% lower incidence of certain cancers, particularly colorectal and breast cancer 17. Randomized trials are ongoing, but no cancer-prevention indication has been filed.

PCOS: Metformin is widely prescribed off-label for polycystic ovary syndrome. The 2023 international evidence-based guideline for PCOS assessment and management recommends metformin for metabolic features when lifestyle changes are insufficient 18. A formal supplemental NDA for PCOS has never been submitted, so the use remains off-label despite decades of clinical data.

Vitamin B12 monitoring: The 2024 ADA Standards of Care recommend periodic B12 measurement in patients on long-term metformin, based on evidence that 5 to 10% of chronic users develop B12 deficiency 5. This is a labeling and practice-guideline change, not a new approval, but it reflects the evolving understanding of metformin's metabolic effects.

Metformin's Position in the GLP-1 Era

The emergence of GLP-1 receptor agonists (semaglutide, tirzepatide) and SGLT2 inhibitors has not displaced metformin. The 2024 ADA/EASD consensus report maintains metformin as first-line therapy for most patients with type 2 diabetes, particularly those without established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease 5. For patients with those comorbidities, the guidelines recommend GLP-1 RAs or SGLT2 inhibitors with proven organ-protection benefits regardless of metformin use.

In practice, metformin remains the most prescribed diabetes medication in the United States. IMS Health data report over 90 million metformin prescriptions dispensed annually. Generic pricing under $10 per month makes it accessible in ways that newer agents priced at $900 to $1,300 per month cannot match for uninsured or underinsured patients.

The drug that arrived in the United States three decades late has become the most durable first-line therapy in diabetes care. Its next regulatory chapter may have nothing to do with glucose at all. The TAME trial's anticipated results around 2027 could redefine what the FDA considers an approvable endpoint, opening a regulatory path for aging itself as a treatable condition 16.